Calidi Biotherapeutics, Inc. (CLDI): Submission of Matters to a Vote of Security Holders
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001855485 0001855485 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
How this was made
The 30-second read
Why it matters
Key items passed include: election of a Class III director (Scott Leftwich), ratification of CBIZ CPAs P.C. as independent auditor for FY ending Dec. 31, 2026, approval of a reverse stock split amendment with a board-selected ratio between 1-for-2 and 1-for-16, and an increase to the 2023 Equity Incentive Plan share authorization from 282,815 to 1,950,000.
Market read
This is primarily a governance/corporate actions clearance event; the reverse-split approval is the main item that could later influence trading once the exact ratio is set.
What to watch
Traders should watch for a subsequent announcement specifying the split ratio and any related financing/compliance actions, since those would be the true catalysts.
Background
The 8-K (Item 5.07) reports final results from Calidi Biotherapeutics’ June 12, 2026 annual meeting of stockholders.
Ticker impact
Calidi Biotherapeutics reported final 8-K voting results, including approval of a reverse stock split range (1-for-2 to 1-for-16) and an auditor ratification.
Near-term volatility possible around implementation/announcement; direction depends on whether the board selects the lower vs higher split ratio and any accompanying financing/compliance messaging.
The filing is a corporate governance update (not a split execution), but reverse-split approvals are often followed by a board decision and can change per-share price/market perception.
Market effects
Reverse-split approvals can be a broader microcap/biotech compliance/liquidity signal, but this filing is company-specific and not sector-wide guidance.
None material beyond US microcap sentiment.
None.
Counterpoint
Because the reverse split ratio is only approved within a range and not yet executed, the market may discount this as largely procedural until the board announces the exact ratio.
Key entities
- issuerCalidi Biotherapeutics, Inc.
Subject of the 8-K; reported shareholder voting results including reverse split approval.
- director_nomineeScott Leftwich
Elected Class III director for a three-year term.
- auditorCBIZ CPAs P.C.
Ratified as independent registered public accounting firm for FY ending Dec. 31, 2026.
